TEL AVIV, Israel, April 5, 2016 — BioLight Life Sciences Ltd., a publically traded ophthalmic technology development firm, has reported its 2015 financial results and said it has achieved all previously announced 2015 milestones.
For the fiscal year ended Dec. 31, 2015, the company reported revenues of New Israeli Shekels (NIS) 1.4 million (about $360,000) from sales of its IOPtiMate System, a laser-based noninvasive surgical treatment for glaucoma.
Net loss for 2015 was approximately NIS 27.6 million ($7.1 million), or NIS 7.98 loss per share, compared to a net loss of approximately NIS 36 million ($9.2 million), or NIS 11.96 loss per share, for 2014. At the close of fiscal 2015, the company had approximately NIS 51 million ($13.1 million) in cash and short-term deposits.
- The branch of medicine involved in the study of the anatomy, functions, diseases and treatments of the eye.
MORE FROM PHOTONICS MEDIA